Articles From: Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference to AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress


2014/11/25
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
2014/12/5
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit investment picks
2014/11/14
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum investment picks
2014/11/5
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Stephens 2014 Fall Investment Conference investment picks
2014/11/12
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference investment picks
Research-Driven Environment and Easy Adaptation to Change Are Key Traits that Scientists Value in their Employers ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Acknowledged by Science Magazine as a Top Employer investment picks
Abbott Declares 364th Consecutive Quarterly Dividend ABBOTT PARK, Ill., Dec.
Sign-up for Abbott Announces Increase in Quarterly Dividend investment picks
SERIES WILL BE RENAMED ABBOTT WORLD MARATHON MAJORS STARTING IN 2015 ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Celebrates the Power of Health and Achievement as First-Ever Title Sponsor of World Marathon Majors investment picks
Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares investment picks
ABBOTT PARK, Ill., Dec.
Sign-up for Abbott Completes Acquisition of Veropharm investment picks
Abbott Enters Large and Growing Catheter-Based Electrophysiology Market with Next-Generation Technologies to Improve Treatment of People with Atrial Fibrillation ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Expands Its Medical Device Business with Acquisition in Catheter-Based Electrophysiology Market investment picks
ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Hosts Conference Call for Third-Quarter Earnings investment picks
Moms Value Paid Parental Leave and Flexible Work Arrangements as Abbott Is Recognized for the Fourteenth Consecutive Year ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Included In Top 10 Best Companies by Working Mother Magazine investment picks
2014/12/12
TIDMABT RNS Number : 6021Z Abbott Laboratories 12 December 2014 Abbott Completes Acquisition of Veropharm ABBOTT PARK, Ill., Dec.
Sign-up for Abbott Laboratories Acquisition investment picks
Shares of Abbott Laboratories (ABT) rose 1.7% in light premarket trade Wednesday, after the drug maker reported better-than-expected third-quarter profit, and lifted the midpoint of its full-year outlook, citing an improved performance in its branded generic pharmaceuticals and nutrition businesses.
Sign-up for Abbott Labs shares rise after profit tops forecasts investment picks
Abbott (ABT) said Friday it is raising its quarterly dividend to 24 cents a share from 22 cents.
Sign-up for Abbott raises quarterly dividend to 24 cents a share from 22 cents investment picks
2014/10/22
- Third-Quarter Adjusted EPS Above Previous Guidance Range, Including Results From Discontinued Operations Related to Mylan Transaction - - Raises Mid-Point of Full-Year 2014 EPS Guidance; Excluding Specified Items, Represents Double-Digit Growth - ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Reports Third-Quarter 2014 Results investment picks
ABBOTT PARK, Ill., Nov.
Sign-up for Abbott to Present at Credit Suisse 2014 Healthcare Conference investment picks
- IRIDICA has the potential to change how pathogens that cause serious infections, such as sepsis and pneumonia, are detected and identified - May provide doctors with information needed to start treating those who are critically ill with appropriate therapies sooner - May help reduce the use of broad-spectrum antibiotics, a leading cause of antibiotic resistance ABBOTT PARK, Ill., Dec.
Sign-up for Abbott's Pioneering, Infectious Disease Testing Platform, IRIDICA, Now Available in Europe investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud and breach of fiduciary duty claims against AbbVie, Inc. (NYSE: ABBV) (“AbbVie” or the “Company”). If you currently own shares of AbbVie and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/ABBV or contact Craig J.
Sign-up for ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty investment picks
- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] - Results show HUMIRA meets primary endpoint in PIONEER II clinical trial - PIONEER II results, together with previously presented PIONEER I results, will contribute to worldwide regulatory filings for an expanded use of HUMIRA AMSTERDAM , Oct.
Sign-up for AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress investment picks
- Will announce third-quarter 2014 financial results on Oct.
Sign-up for AbbVie Announces New $5 Billion Stock Repurchase Program and Increases Dividend investment picks
By Shayndi Raice Pharmaceutical giant AbbVie Inc. officially reversed course on its plans to buy Dublin's Shire PLC, saying it was recommending shareholders vote against the $54 billion takeover deal it had signed in July in light of new tax rules from the U.S. Treasury Department.
Sign-up for AbbVie board recommends shareholders vote against Shire deal investment picks
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION NORTH CHICAGO, Ill.
Sign-up for AbbVie Board Recommends Stockholders Vote Against Shire Transaction investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie Declares Quarterly Dividend investment picks
Data from 25 accepted abstracts include results from: --
Sign-up for AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Washington's efforts to thwart so-called "inversion" deals that avoid U.S. taxes scored a victory of sorts Monday as AbbVie Inc. formally ended its proposed transaction to acquire Irish drug maker Shire PLC.
Sign-up for AbbVie formally scuttles deal to buy Shire investment picks
- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer - Additional results to be presented on a Phase 1 trial in Japanese patients with NSCLC NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference to AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent